STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...
Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a ...
Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,500 shares of the company on 01-10-2025. This trade was reported by Quiver Quantitative using data from a ...
Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Greenwich LifeSciences (GLSI – Research Report) ...
Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback